ERRATUM The Impact of Preoperative Serum Anti-TNFa Therapy Levels on Early Postoperative Outcomes In Inflammatory Bowel Disease Surgery: Erratum Due to an author error, accurate disclosure statements were not published for the authors of the article, ‘‘The impact of preoperative serum anti-TNFa therapy levels on early postoperative outcomes in inflammatory bowel disease surgery,’’ which published in the March 2015 issue of Annals of Surgery. At the time of publication, Dr. Dubinsky was a consultant to Prometheus Laboratories, Janssen Pharmaceuticals and AbbVie, Inc; Dr. McGovern was a consultant to Janssen and UCB Pharmaceuticals; Dr. Melmed had received research funding from Prometheus Laboratories and was a consultant to AbbVie, Inc., Janssen Pharmaceuticals and UCB; Dr. Targan was a consultant to Prometheus Laboratories and Janssen Pharmaceuticals; Dr. Vasiliauskas was at one time on the speaker’s bureau for Prometheus Labs. REFERENCE 1. Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFa therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg. 2015;261:487–496. e62 | www.annalsofsurgery.com Annals of Surgery Volume 267, Number 3, March 2018 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Annals of Surgery – Wolters Kluwer Health
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud